ERBB2 and breast cancer: TNBC tumors are insensitive to some of the most effective targeted therapies available for breast cancer treatment including endocrine therapies such as tamoxifen, aromatase inhibitors or fulvestrant and HER-2-directed therapy such as trastuzumab (27).